The vaccine to prevent this disease arrives in Guatemala.
Guatemala welcomes an innovative vaccine to prevent Herpes Zoster (HZ), marking a significant milestone in protecting the health of the population by providing an effective way to prevent the reactivation of the varicella zoster virus (VZV), responsible of causing this disease.
Herpes Zoster (HZ) is a painful disease that is estimated to affect 1 in 3 people during their lifetime. Immunocompetent adults over the age of 50 and immunocompromised people (those with a weakened immune system) are at increased risk of contracting Shingles and associated complications. The options for the treatment of this virus and its complications, among which Postherpetic Neuralgia (PHN) stands out, are complex clinical problems with constant uncertainties and active research.
Dr. Salvatore Ferraro, pediatric infectious disease specialist and medical manager at GSK, says: “Shingles is not just a painful rash; It is a disease that can leave serious consequences. Approximately 10% to 18% of affected people will experience Postherpetic Neuralgia (PHN), persistent nerve pain that can last months or even years after the rash disappears. Additionally, up to 25% of shingles cases may involve ocular complications known as Herpes Zoster Ophthalmicus (HZO), which in rare cases can lead to vision loss.”
Knowing and preventing the complications of shingles is crucial to protecting people’s health and well-being. Vaccination can be an effective tool to reduce both the incidence of this disease and the risk of developing sequelae. In an older and vulnerable adult population, the vaccine, with a two-dose schedule, not only helps mitigate long-term treatment costs, but also provides long-lasting immunity against this debilitating disease.
Guatemala: Preventing Herpes Zoster is POSSIBLE
In Guatemala, a significant milestone is marked with the launch of this vaccine produced in Belgium, which has a powerful immunizing agent. By introducing this solution to prevent shingles, GSK pharmaceutical laboratory demonstrates its continued commitment to providing innovative solutions that address global healthcare needs.
During the events that framed its launch, the arrival of this vaccine attracted a prominent audience of media and health professionals with approximately 300 attendees, including doctors from various specialties. The meeting allowed us to explore the importance of the prevention of Herpes Zoster and the introduction of the new vaccine. The participation of prominent specialists reflected the firm commitment of the medical community to promoting the health and well-being of patients in the country.
«The GSK vaccine has been approved by the European Medicines Agency (EMA) since March 2018 for the prevention of herpes zoster (HZ) and Postherpetic Neuralgia (PHN) in adults aged 50 years and over. Its superior effectiveness makes it a highly reliable option: it provides robust protection against Shingles and post-herpetic neuralgia (PHN). In adults over 50 years of age, the vaccine is 97% effective, while in those 70 years of age or older, it maintains an efficacy of 91%. “This impressive protection rate highlights the safety and efficiency of the vaccine in preventing these debilitating conditions.” commented Dr. Nancy Sandoval, infectious disease specialist and internist.
With the successful launch of this vaccine in Guatemala, GSK has consolidated its leadership in preventive healthcare and reaffirmed its commitment to innovation to improve the quality of life of Guatemalans.
Fuente. GSK